← Oncology Approval Tracker

FDA DECISION ·

Hyrnuo

sevabertinib · Bayer Healthcare Pharmaceuticals

Accelerated approvalNew therapyNon-small cell lung cancer
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

For adults with locally advanced or metastatic nonsquamous NSCLC with a HER2 (ERBB2) activating tyrosine kinase domain mutation by an FDA-approved test after prior systemic therapy.

LAMPGEN ANALYSIS

Why it matters

Accelerated approval added another oral kinase inhibitor option for previously treated HER2-mutated nonsquamous lung cancer.

What research teams should watch

Record prior HER2-directed therapy, retain the exact qualifying variant, and coordinate follow-up for confirmatory evidence.

PRIMARY RECORDS

Sources